Glucosylceramide has been widely studied in the context of Lewy body diseases, where it has been demonstrated to precipitate the toxic conversion of α-synuclein (Zunke et al. 2018), and thus, its elevation in Niemann–Pick type C1 may contribute vulnerability to α-synuclein aggregation. The gene discussed is SNCA; the disease is Lewy body dementia.